Market research

Global Urinary Tract Infection Therapeutics Market Worth to Reach USD 11,560 Million By 2027

Facts and Factors Market Research has published a new report titled “Urinary Tract Infection Therapeutics Market By Age Group (Adults, Elderly, and Children), by Indication (Uncomplicated, Recurrent, Complicated, and Catheter Associated), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce), and by Drug Type (Quinolones, Azoles & Amphotericin B, Aminoglycoside, Penicillin & Combinations, Cephalosporin, Nitrofurans, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2019–2027”.

According to the report, the global urinary tract infection therapeutics market was valued approximately USD 8,437 million in 2018 and is expected to reach a value of around USD 11,560 million by 2027, at a CAGR of around 3.6% between 2019 and 2027.

Urinary tract infections, also commonly known as UTIs, are caused by microbes. These microbes are generally bacteria. However, viral and fungal infections can also cause UTIs. Majority of the UTIs affect the urethra and bladder, although these may occur anywhere in the urinary tract, i.e., kidneys, uterus, bladder, and urethra. The UTIs affecting the upper tract, i.e., uterus and kidneys, occur rarely but can be extremely serious in nature in comparison to the lower tract UTIs. Generally, different UTIs call for a different method of treatment, which is based on infection cause. Thus, doctors and physicians prescribe drugs depending on the organism type responsible for the specific UTI.

Request Free Sample Copy of Research Report @

This Free report sample includes:


  • A brief introduction to the research report.
  • Graphical introduction of the regional analysis.
  • Top players in the market with their revenue analysis.
  • Selected illustrations of market insights and trends.
  • Example pages from the report.
  • FnF research methodology.

Rising UTI incidences majorly driving the urinary tract infection therapeutics market

The globally increasing incidence of urinary tract infections among men is driving the urinary tract infection therapeutics market. Women are more prone to UTIs than men due to their shorter urethras. E. Coli bacterium is the most bacteria type that causes UTIs. The UTI-causing microbes enter the urethra and travel up the bladder and kidneys, which can have adverse effects on the individual’s health.

In addition, the urinary tract infection therapeutics market is also fuelled by the escalating population of the elderly across the world, particularly above the age of 60. Since the geriatric population is more prone to diabetes, they are at a much higher risk of suffering from urinary tract infections. Hospital-acquired infections are common among senior citizens.

Uncomplicated UTI is projected to dominate the indication segment

The uncomplicated UTI segment was worth USD 5,092 million in 2017. Uncomplicated UTIs are the most common type of UTIs affecting the global population currently. Mostly, antibiotics are recommended to treat these UTIs. The uncomplicated UTI segment is likely to dominate the market for urinary tract infection therapeutics in the year ahead, owing to the increasing hospital-acquired infections, precisely catheter-associated UTIs.

Inquire more about this report before purchase @

(You may enquire a report quote OR available discount offers to our sales team before purchase.)

Hospital pharmacies are the largest market segment

The hospital pharmacies segment is the segment of the urinary tract infection therapeutics. It generated revenue worth USD 5,323 million in 2017 and is projected to grow rapidly in the years ahead. Additionally, the retail pharmacies segment is anticipated register decent CAGR globally in the future.

Asia Pacific to record the highest CAGR in the years ahead

Improving healthcare facilities, rising awareness about UTI and its various treatment options, and increasing government initiatives for healthcare spending will propel the urinary tract infection therapeutics market in the Asia Pacific to record the highest CAGR globally. In 2017, the Asia Pacific market for urinary tract infection therapeutics was worth USD 1,962 million.

Key players operating in the urinary tract infection therapeutics market are Zavante Therapeutics, Urigen, Shionogi, Novo Nordisk, Mylan, MerLion Pharmaceuticals, MediciNova, Lipella Pharmaceuticals, Dr. Reddy’s Laboratories, Bayer, Cipla, AstraZeneca, Aquinox, ALLERGAN, Achaogen, C.H. Boehringer Sohn, F. Hoffmann-La Roche, Pfizer, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries, Novartis, GlaxoSmithKline, and Johnson & Johnson, among others.

Request customized copy of report @

(We customize your report according to your research need. Ask our sales team for report customization)

This report segments the urinary tract infection therapeutics market as follows:

Global Urinary Tract Infection Therapeutics Market: By Age Group Analysis

  • Adults
  • Elderly
  • Children

Global Urinary Tract Infection Therapeutics Market: By Indication Analysis

  • Uncomplicated UTI
  • Complicated UTI
  • Recurrent UTI
  • Catheter Associated UTI

Global Urinary Tract Infection Therapeutics Market: By Distribution Channel Analysis

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Global Urinary Tract Infection Therapeutics Market: By Drug Type Analysis

  • Quinolones
  • Azoles and Amphotericin B
  • Aminoglycoside
  • Penicillin and Combinations
  • Cephalosporin
  • Nitrofurans
  • Others

Global Market: By Region Analysis

  • North America
    • U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our client’s/customer’s conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,
8 Century Avenue, Shanghai,
Postal – 200120, China
Tel: +86 21 80360450





Related Articles

Back to top button